Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
about
A review of anti-VEGF agents for proliferative diabetic retinopathyDiabetic Retinopathy-Update on Prevention Techniques, Present Therapies, and New Leads.Emerging roles for antiangiogenesis factors in management of ocular disease.Systematic review and meta-analysis of 16 randomized clinical trials of radix astragali and its prescriptions for diabetic retinopathy.Protective measures against ultrafiltration failure in peritoneal dialysis patientsAdverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureIntravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathyComplications of intravitreal injections in patients with diabetes.Mild endoplasmic reticulum stress promotes retinal neovascularization via induction of BiP/GRP78.Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.Intravitreal administration of bevacizumab: pros and cons.Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.Imbalance of the Nerve Growth Factor and Its Precursor: Implication in Diabetic Retinopathy.Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema.
P2860
Q27025643-FCD46263-29AE-4292-868F-103005AA6474Q34553087-147B26D5-1298-4610-8E04-A456D0499F78Q36696513-8F54B2CE-7452-466A-9E69-71754C1462BDQ36746311-28DA60BD-A18A-4083-8B2D-46F5510ABF44Q37970606-1B086044-A453-4643-8802-AF2CEC9758D3Q38110731-804E8F67-2D2B-4ECD-A58C-708950962CACQ38193826-2FD23C13-5E17-4A97-B033-CF4590FC5231Q38261106-069FBB51-569F-4B84-A612-9ECEFBDC67D0Q39356067-6E470CE4-CBB5-4EAD-84A6-00C079E856D2Q39357577-92F82E78-7403-4B69-A0EF-EECE9CE8F10FQ39865676-87E9DEA2-6459-4B5A-9096-2035539B0AFFQ41091625-3183E17E-49AD-4001-9C9A-79E803433DA1Q41839716-EF8040DB-C860-4E5F-B311-67080FD2D91AQ51701226-6AFF5823-62AE-4EB0-A08D-1A4CDFE4769A
P2860
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
@ast
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
@en
type
label
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
@ast
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
@en
prefLabel
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
@ast
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
@en
P2093
P2860
P356
P1476
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
@en
P2093
Andres F Lasave
Arturo A Alezzandrini
J Fernando Arevalo
Juan G Sanchez
Maria H Berrocal
Mario Saravia
Michel Eid Farah
Miguel Brito
Natalia Restrepo
P2860
P304
P356
10.1155/2011/584238
P577
2011-03-30T00:00:00Z